Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epaldeudomide (KPG-818) in Hematological Malignancies
NCT04283097Phase 1Completed
- Sponsor
- Kangpu Biopharmaceuticals
- Start
- Sep 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epaldeudomide in multiple myeloma (MM), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and 4 more, sponsored by Kangpu Biopharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events at 6 months and Recommended Phase 2 Dose at 4 weeks. Started Sep 2021; status: completed.
02
Drugs
epaldeudomide
03
Conditions
multiple myeloma (MM)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)adult T-cell leukemia-lymphoma (ATLL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04283097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04283097.